雷公藤甲素联合人参皂苷Rg3免疫治疗胰腺癌研究  

Immunotherapy of pancreatic cancer with triptolide combined with ginsenoside Rg3

作　　者：赵文文 江婷婷 王志荣 汪云云 武香香[2] 曾华辉[2] ZHAO Wen-wen;JIANG Ting-ting;WANG Zhi-rong;WANG Yun-yun;WU Xiang-xiang;ZENG Hua-hui(College of Pharmacy,Henan University of Traditional Chinese Medicine,Zhengzhou 450046,China;College of Chinese Medicine,Henan University of Chinese Medicine,Zhengzhou 450046,China)

机构地区：[1]河南中医药大学药学院,河南郑州450046 [2]河南中医药大学中医药科学院,河南郑州450046

出　　处：《药学学报》2024年第6期1794-1803,共10页Acta Pharmaceutica Sinica

基　　金：河南省科技研发计划联合基金(优势学科培育类)-培育项目(222301420060);河南省优秀青年基金(212300410057);河南省自然科学基金面上项目(222300420482).

摘　　要：本研究以脂质体作为载体包载雷公藤甲素与人参皂苷Rg3,治疗胰腺癌荷瘤小鼠,探讨脂质体对胰腺癌肿瘤微环境免疫因子CD4^(+)、CD8^(+)的水平影响,并对抑瘤效果和安全性进行评价。研究采用Pan02细胞构建荷瘤C57BL/6小鼠模型,经过14天治疗,观测荷瘤小鼠肿瘤体积变化和体重变化。结果表明,脂质体高、低剂量相对于模型组肿瘤体积有明显治疗效果(P<0.01),脂质体高剂量相对于雷公藤甲素组抑瘤率有明显提高(P<0.05),免疫组化表明,与模型组相比,脂质体高剂量组能上调免疫因子CD4^(+)/CD8^(+)比值,且能抑制肿瘤增殖因子表达,促进肿瘤凋亡因子表达,经过肝、脾、肺、肾的病理苏木素−伊红染色和血清因子检测有较高的安全性。该实验方案已通过河南中医药大学实验动物伦理委员会审核批准(编号:DWLL202103173),动物福利和实验过程均遵循河南中医药大学实验动物伦理委员会的规定。本研究为胰腺癌免疫治疗探索提供了一种新的思路。Liposome was used as carrier to carry triptolide and ginsenoside Rg3 in the treatment of pancreatic cancer tumor mice.The effects of liposome on the levels of CD4^(+)and CD8^(+)microenvironmental immune factors of pancreatic cancer tumor were investigated,and the tumor inhibitory effect and safety were evaluated.In this study,Pan02 cells were used to construct a tumor-bearing C57BL/6 mouse model.After 14 days of treatment,the changes in tumor volume and body weight of tumor-bearing mice were observed.The results showed that the high and low doses of liposome had significant therapeutic effect on tumor volume in the model group(P<0.01),and the tumor inhibition rate of high doses of liposome was significantly increased compared with triptolide group(P<0.05).Immunohistochemistry showed that compared with the model group,the tumor inhibition rate of liposome was significantly increased.The high-dose liposome group can up-regulate the ratio of immune factor CD4^(+)/CD8^(+),inhibit the expression of tumor proliferation factor and promote the expression of tumor apoptosis factor,and has a high safety after pathological hematoxylin and eosin staining of liver,spleen,lung and kidney and serum factor detection.Animal welfare and experimental procedures are in accordance with the regulations of the Experimental Animal Ethics Committee of Henan University of Chinese Medicine(approval No.:DWLL202103173).This study provides a new idea for the exploration of immunotherapy for pancreatic cancer.

关 键 词：脂质体 雷公藤甲素 人参皂苷RG3 胰腺癌 免疫治疗 T细胞 

分 类 号：R928[医药卫生—药学]